BioXcel Therapeutics ( NASDAQ:BTAI – Free Report ) had its price objective cut by HC Wainwright from $60.00 to $11.00 in a research note issued to investors on Friday morning, MarketBeat Ratings reports. They currently have a buy rating on the stock. BTAI has been the subject of a number of other research reports. Canaccord Genuity Group decreased their price target on BioXcel Therapeutics from $75.00 to $20.00 and set a buy rating for the company in a report on Tuesday. Bank of America reduced their target price on BioXcel Therapeutics from $43.

https://www.dailypolitical.com/2023/08/19/bioxcel-therapeutics-nasdaqbtai-price-target-cut-to-11-00-by-analysts-at-hc-wainwright.html

#dailypolitical